Key result
Pre-treatment with 1668-thioate attenuated cardiac hypertrophy and inflammation following pressure overload in mice, delaying the loss of cardiac function.
Why the study?
Does pre-treatment with synthetic oligonucleotides attenuate pressure overload-induced inflammation and cardiac hypertrophy in mice?
Does pre-treatment with synthetic oligonucleotides attenuate pressure overload-induced inflammation and cardiac hypertrophy in mice?
Pre-treatment with the synthetic TLR9 ligand 1668-thioate attenuates cardiac hypertrophy, inflammation, and fibrosis following pressure overload in a mouse model, preserving left ventricular function.
Answers are grounded in this paper and cite their sources.
Does not support clinical use; leaves open TLR9 ligand investigation in pressure-overload models.
AIMS: Inflammation and Toll-like receptor (TLR) signalling have been linked to the development of cardiac hypertrophy following transverse aortic constriction (TAC). In the present study, we investigated whether pre-treatment with the synthetic TLR9 ligands 1668-thioate or 1612-thioate modulates the progression of TAC-induced cardiac inflammation and hypertrophy. METHODS AND RESULTS: C57BL/6N-mice were pre-treated with 1668-thioate, 1612-thioate (0.25 nmol/g, i.p.), or phosphate-buffered saline 16 h prior to TAC or sham surgery. Heart-weight/body-weight ratio (HW/BW), cardiomyocyte cell size, cellular macrophage accumulation, myofibroblast differentiation, and collagen deposition were investigated for up to 28 days. Cardiac function was monitored using a pressure-volume catheter and M-mode echocardiography. Inflammatory gene expression in the heart was analysed via gene array, while the time course of mRNA expression of key inflammatory mediators was assessed via RT-qPCR. TAC increased the HW/BW ratio and cardiomyocyte cell size and induced macrophage accumulation, myofibroblast differentiation, and collagen deposition. These changes were accompanied by cardiac inflammation and a significant loss of left ventricular function. Pre-treatment with cytosine-phosphate-guanine (CpG)-containing 1668-thioate attenuated the inflammatory response, the progression of cardiac hypertrophy, and cardiac remodelling, which resulted in a prolonged preservation of left ventricular function. These changes were induced to a smaller extent by the use of the non-CG-containing oligodeoxynucleotide 1612-thioate. CONCLUSION: Pre-treatment with 1668-thioate attenuated cardiac hypertrophy following pressure overload, possibly by modifying the hypertrophy-induced inflammatory response, thereby reducing cardiac growth and fibrosis as well as delaying loss of cardiac function.
No takes yet. Share an insight, caveat, or question.
Velten et al. (2012) studied Cardiac hypertrophy and inflammation following pressure overload. 1668-thioate or 1612-thioate vs. Phosphate-buffered saline was evaluated on Heart-weight/body-weight ratio, cardiomyocyte cell size, cellular macrophage accumulation, myofibroblast differentiation, and collagen deposition. Pre-treatment with 1668-thioate attenuated cardiac hypertrophy and inflammation following pressure overload in mice, delaying the loss of cardiac function.
Synapse has enriched 10 related papers. Consider them for comparative context: